Clinical Pharmacokinetics

, Volume 26, Issue 3, pp 233–242 | Cite as

Pharmacokinetic Optimisation of the Treatment of Osteoarthritis

  • Kenneth J. Skeith
  • Dion R. Brocks
Review Article Pharmacokinetics-Therapeutics


Osteoarthritis is the most frequently encountered form of arthritis worldwide. Pharmacological therapies consisting of nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics such as paracetamol (acetaminophen), codeine and dextropropoxyphene are the principal means of symptom control. Osteoarthritis appears to have little impact on the pharmacokinetics of these drugs per se. However, other clinical features commonly associated with patients with osteoarthritis, such as advanced age, obesity or concurrent diseases and medications, may be important.

A limited number of concentration-response studies have demonstrated the existence of a pharmacokinetic/pharmacodynamic relationship for these drugs. However, the information derived from patients with osteoarthritis is very limited. Simple analgesics have been shown to be as effective as NSAIDs in some studies. Furthermore, the response does not appear to be able to be predicted on the basis of clinical features of inflammation.

It appears that a defined concentration-toxicity relationship exists and should be considered when dosage regimens for patients are formulated. Symptoms occur with a circadian rhythm, and similarly, there is circadian variation in the pharmacokinetic/pharmacodynamic response of a number of NSAIDs in patients with osteoarthritis. Selection of the optimal drug formulation will also be influenced by the need for continuous or intermittent therapy in these patients.


Osteoarthritis Ibuprofen Ketoprofen Clinical Pharmacokinetic Etodolac 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abernethy DR, Greenblatt DJ. Pharmacokinetics of drugs in obesity. Clinical Pharmacokinetics 7: 108–124, 1982PubMedCrossRefGoogle Scholar
  2. Abernethy DR, Greenblatt DJ. Ibuprofen disposition in obesity. Arthritis and Rheumatism 28: 1117–1121, 1985PubMedCrossRefGoogle Scholar
  3. Adams SS. Non-steroidal, anti-inflammatory drugs, plasma half-lives, and adverse reactions. Lancet 2: 1204–05, 1987PubMedCrossRefGoogle Scholar
  4. Al Arfag A, Davis P. Osteoarthritis 1991: Current drug treatment regimens. Drugs 41: 193–201, 1991PubMedCrossRefGoogle Scholar
  5. Altman RD. Laboratory findings in osteoarthritis. In Moskowitz et al. (Eds) Osteoarthritis: diagnosis and medical/surgical management, 2nd ed., pp. 313–328, WB Saunders, Philadelphia, 1992Google Scholar
  6. Avgerinos A, Hutt AJ. Interindividual variability in the enantiomeric disposition of ibuprofen following the oral administration of the racemic drug to healthy volunteers. Chirality 2: 249–256, 1990PubMedCrossRefGoogle Scholar
  7. Batchlor EE, Paulus HE. Principles of drug therapy. In Moskowitz et al. (Eds) Osteoarthritis: diagnosis and medical/surgical management, 2nd ed, pp. 465–492, WB Saunders, Philadelphia, 1992Google Scholar
  8. Bollet AJ. Analgesic and anti-inflammatory drugs in the therapy of osteoarthritis. Seminars in Arthritis and Rheumatism 11 (Suppl. 1): 130–132, 1981CrossRefGoogle Scholar
  9. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison of an antiinflammatory dose of ibuprofen, and analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. New England Journal of Medicine 325: 87–91, 1991PubMedCrossRefGoogle Scholar
  10. Borda IT. The spectrum of adverse gastrointestinal effects associated with nonsteroidal anti-inflammatory drugs. In Borda & Koff (Eds) NSAIDs: a profile of adverse effects, pp. 25–80, Hanley & Belfus Inc., Philadelphia, 1992Google Scholar
  11. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic. Journal of Rheumatology 19: 1950–1954, 1992aPubMedGoogle Scholar
  12. Bradley JD, Rudy AC, Katz BP, Ryan SI, Kalasinski LA, et al. Correlation of serum concentrations of ibuprofen stereoisomers with clinical response in the treatment of hip and knee osteoarthritis. Journal of Rheumatology 19: 130–134, 1992bPubMedGoogle Scholar
  13. Brocks DR, Jamali F. Clinical pharmacokinetics of ketorolac tromethamine. Clinical Pharmacokinetics 23: 415–427, 1992PubMedCrossRefGoogle Scholar
  14. Bruguerolle B, Desnuelle C, Jadot G, Valli M, Aquaviva PC. Chronopharmacocinétique de l’indométhacine à effet prolongé en pathologie rhumatismale. Revue International du Rhumatisme 13: 263–267, 1983Google Scholar
  15. Carson JL, Strom BL, Soper KA, West SL, Morse ML. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Archives of Internal Medicine 147: 85–88, 1987PubMedCrossRefGoogle Scholar
  16. Clench J, Reinberg A, Dziewanowska Z, Ghata J, Smolensky M. Circadian changes in the bioavailability and effects of indomethacin in healthy subjects. European Journal of Clinical Pharmacology 20: 359–369, 1981PubMedCrossRefGoogle Scholar
  17. Day RO, Furst DE, Dromgoole SH, Kramm B, Roe R, et al. Relationship of serum naproxen concentration to efficacy in rheumatoid arthritis. Clinical Pharmacology and Therapeutics 31: 733–740, 1982PubMedCrossRefGoogle Scholar
  18. Day RO, Nguyen T, Williams KM. Tenoxicam dose concentration response relationship in rheumatoid arthritis. Abstract. Clinical Pharmacology and Therapeutics 53: 152, 1993Google Scholar
  19. D’Arienzo M, Pennisi M, Zanolo G, Borsa M. Ketoprofen lysine: ketoprofen serum levels and analgesic activity. Drugs in Experimental and Clinical Research 10: 863–866, 1984Google Scholar
  20. Desmeules J, Dayer P, Gascon MP, Magistris M. Impact of genetic and environmental factors on codeine analgesia. Abstract. Clinical Pharmacology and Therapeutics 45: 122, 1989Google Scholar
  21. Eason CT, Bonner FW, Parke DV. The importance of pharmacokinetic and receptor studies in drug safety evaluation. Regulatory Toxicology and Pharmacology 11: 288–307, 1990PubMedCrossRefGoogle Scholar
  22. Forrest JAH, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clinical Pharmacokinetics 7: 93–107, 1982PubMedCrossRefGoogle Scholar
  23. Furst DE. Clinical significance of long versus short serum half-life in NSAIDs. In Famaey & Paulus (Eds) Therapeutic applications of NSAIDs, pp. 359–372, Marcel Dekker, New York, 1992Google Scholar
  24. Ghosh P, Smith M, Wells C. Second-line agents in osteoarthritis. In Dixon & Furst (Eds) Second-line agents in the treatment of rheumatic diseases, pp. 363–427, Marcel Dekker, New York, 1992Google Scholar
  25. Gonzalez FJ, Meyer VA. Molecular genetics of the debrisquin-sparteine polymorphism. Clinical Pharmacology and Therapeutics 50: 233–238, 1991PubMedCrossRefGoogle Scholar
  26. Grennan DM, Aarons L, Siddiqui M, Richards M, Thompson R, et al. Dose-response study with ibuprofen in rheumatoid arthritis: clinical and pharmacokinetic findings. British Journal of Clinical Pharmacology 15: 311–316, 1983PubMedCrossRefGoogle Scholar
  27. Guissou P, Cuisinaud G, Lorca G, Lejeune E, Sassard J. Chronopharmacokinetic study of a prolonged release form of indomethacin. European Journal of Clinical Pharmacology 24: 667–670, 1983PubMedCrossRefGoogle Scholar
  28. Hamdy RC, Murnane B, Perera N, Woodcock K, Koch IM. The pharmacokinetics of benoxaprofen in elderly subjects. European Journal of Rheumatology and Inflammation 5: 69–75, 1982PubMedGoogle Scholar
  29. Jacobs J, Goldstein AG, Kelly ME, Bloom BS. NSAID dosing schedule and compliance. Drug Intelligence and Clinical Pharmacy 22: 727–728, 1988PubMedGoogle Scholar
  30. Kamal A, Koch IM. Pharmacokinetic studies of benoxaprofen in geriatric patients. European Journal of Rheumatology and Inflammation 5: 76–81, 1982PubMedGoogle Scholar
  31. Kohler G, Primbs P, Morand J, Rubelt CH. Correlation between ketoprofen plasma levels and analgesic effect in acute lumbar pain and radicular pain. Clinical Rheumatology 4: 399–404, 1985PubMedCrossRefGoogle Scholar
  32. Laska EM, Sunshine A, Marrero I. The correlation between blood levels of ibuprofen and clinical analgesic response. Clinical Pharmacology and Therapeutics 40: 1–7, 1986PubMedCrossRefGoogle Scholar
  33. Lawrence JS, Bremner JM, Bier F. Osteo-arthrosis. Prevalence in the population and relationship between symptoms and x-ray changes. Annals of Rheumatic Diseases 25: 1–24, 1966Google Scholar
  34. Lawrence RC, Hochberg MC, Kelsey JL, McDuffie FC, Medsger Jr TA, et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. Journal of Rheumatology 16: 427–441, 1989PubMedGoogle Scholar
  35. Levi F, Le Louarn C, Reinberg A. Chronotherapy of osteoarthritic patients: optimization of indomethacin sustained release (ISR). Annual Review of Chronopharmacology 1: 345–348, 1984Google Scholar
  36. Lin JH, Cocchetto DM, Duggan DE. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clinical Pharmacokinetics 12: 402–432, 1987PubMedCrossRefGoogle Scholar
  37. Needs CJ, Brooks PM. Clinical pharmacokinetics of the salicylates. Clinical Pharmacokinetics 10: 164–177, 1985PubMedCrossRefGoogle Scholar
  38. Netter P, Bannwaith B, Lapicque F, Abiteboul M, Lequintrec JS, et al. Influence of synovial fluid concentrations of ketoprofen on PGE2 and arthritic pain. Abstract. Clinical Pharmacology and Therapeutics 53: 152, 1993Google Scholar
  39. Netter P, Bannwarth B, Royer-Morrot MJ. Recent findings in the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid. Clinical Pharmacokinetics 17: 145–162, 1989PubMedCrossRefGoogle Scholar
  40. Ollagnier M, Decousus H, Cherrah Y, Levi F, Mechkouri M, et al. Circadian changes in the pharmacokinetics of oral ketoprofen. Clinical Pharmacokinetics 12: 367–378, 1987PubMedCrossRefGoogle Scholar
  41. Orme M. NSAIDs in the healthy elderly. In Famaey & Paulus (Eds) Therapeutic applications of NSAIDs, pp. 191–210, Marcel Dekker, New York, 1992Google Scholar
  42. Orme MLE. Plasma concentrations and therapeutic effect of anti-inflammatory and anti-rheumatic drugs. Pharmacology and Therapeutics 16: 167–180, 1992CrossRefGoogle Scholar
  43. Owen JA, Sitar DS, Berger L, Brownell L, Duke PC, et al. Age-related morphine kinetics. Clinical Pharmacology and Therapeutics 34: 364–368, 1983PubMedCrossRefGoogle Scholar
  44. Peyron JG, Altman RD. The epidemiology of osteoarthritis. In Moskowitz et al. (Eds), Osteoarthritis: diagnosis and medical/surgical management, pp. 15–37, WB Saunders, Philadelphia, 1992Google Scholar
  45. Porter RS. Factors determining efficacy of NSAIDs. Drug Intelligence and Clinical Pharmacy 18: 42–51, 1984PubMedGoogle Scholar
  46. Reinberg A, Manfredi R, Kahn MF, Chaouat D, Chaouat Y, et al. Tenoxicam chronotherapy of rheumatoid diseases. Annual Review of Chronopharmacology 7: 293–296, 1990Google Scholar
  47. Rudy AC, Bradley JD, Ryan SI, Kalasinski LA, Xiaotao Q, et al. Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients. Therapeutic Drug Monitoring 14: 464–470, 1992PubMedCrossRefGoogle Scholar
  48. Runkel R, Forchielli E, Sevelius H, Chaplin M, Segre E. Nonlinear plasma level response to high doses of naproxen. Clinical Pharmacology and Therapeutics 15: 261–266, 1974PubMedGoogle Scholar
  49. Sanders PA, Grennan DM. Non-steroidal anti-inflammatory drugs versus simple analgesics in the treatment of arthritis. Baillière’s Clinical Rheumatology 4: 371–385, 1990PubMedCrossRefGoogle Scholar
  50. Scatina J, Hicks D, Kraml M, Weidler D, Garg D, et al. Etodolac kinetics in the elderly. Clinical Pharmacology and Therapeutics 39: 550–553, 1986PubMedCrossRefGoogle Scholar
  51. Smith GL, Goulbourn RA, Burt RAP, Chatfield DH. Preliminary studies of absorption and excretion of benoxaprofen in man. British Journal of Clinical Pharmacology 4: 585–590, 1977PubMedCrossRefGoogle Scholar
  52. Triggs EJ, Nation RL, Long A, Ashley JJ. Pharmacokinetics in the elderly. European Journal of Clinical Pharmacology 8: 55–62, 1975PubMedCrossRefGoogle Scholar
  53. Verbeeck RK, Branch RA, Wilkinson GR. Drug metabolites in renal failure: pharmacokinetics and clinical implications. Clinical Pharmacokinetics 6: 329–345, 1981PubMedCrossRefGoogle Scholar
  54. Wallis WJ, Simkin PA. Anti-rheumatic drug concentration in human synovial fluid and synovial tissue: observation on extravascular pharmacokinetics. Clinical Pharmacokinetics 8: 496–522, 1983PubMedCrossRefGoogle Scholar
  55. Woodhouse KW, Wynne H. The pharmacokinetics of nonsteroidal anti-inflammatory drugs in the elderly. Clinical Pharmacokinetics 12: 111–122, 1987PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Kenneth J. Skeith
    • 1
  • Dion R. Brocks
    • 2
  1. 1.Division of Rheumatology and Faculty of PharmacyUniversity of AlbertaEdmontonCanada
  2. 2.SmithKline Beecham PharmaceuticalsKing of PrussiaUSA

Personalised recommendations